Plain-English translation of NCT07045571 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Pancreatic cancer is often found too late, when it's harder to treat. This study is testing a new approach using a blood test that looks for specific DNA patterns called methylation signatures that may indicate cancer. Researchers hope this simple blood test could help doctors catch pancreatic cancer earlier and predict which treatments will work best for each patient.
Most pancreatic cancers are discovered when they're already advanced, making them difficult to treat successfully. This study exists to find a non-invasive, affordable way to spot pancreatic cancer early and monitor patients after surgery, which could help improve survival rates.
You likely qualify if…
You likely don't qualify if…
You would have blood drawn and provide a tissue sample (either from surgery or a biopsy). Researchers will examine these samples to identify specific methylation patterns that may help predict your cancer's behavior and treatment response. The study involves up to 1,000 patients, and you would be followed to see how well these blood-based markers work compared to traditional diagnostic methods.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China
Sponsor
Yingbin Liu, MD, PhD, FACS
Collaborators
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Enrollment target
~1,000 participants
Started
October 2022
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yinbin Liu, PhD
RenJi Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.